Home > Boards > US Listed > Biotechs > Lineage Cell Therapeutics, Inc. (LCTX)

see POST #1135 for whats moving the

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
ahab333 Member Profile
 
Followed By 30
Posts 3,536
Boards Moderated 0
Alias Born 04/27/11
160x600 placeholder
Lineage Cell Therapeutics (LCTX) Gets a Buy Rating from Noble Financial TipRanks - 12/1/2021 8:15:17 AM
Lineage Cell Therapeutics (LCTX) Gets a Buy Rating from H.C. Wainwright TipRanks - 11/30/2021 11:15:17 AM
Lineage Reports Fourth Case of Retinal Tissue Restoration With OpRegen® Business Wire - 11/30/2021 8:00:00 AM
OpRegen® Clinical Data Presented at 125th Annual American Academy of Ophthalmology Meeting by Michael S. Ip, M.D. Business Wire - 11/15/2021 8:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/10/2021 4:18:34 PM
Lineage Cell Therapeutics EPS in-line, beats on revenue Seeking Alpha - 11/10/2021 4:15:24 PM
Lineage Reports Third Quarter 2021 Financial Results and Highlights Progress From Clinical Cell Therapy Programs Business Wire - 11/10/2021 4:05:00 PM
Lineage Cell Therapeutics Q3 2021 Earnings Preview Seeking Alpha - 11/9/2021 5:35:13 PM
Lineage Cell Therapeutics to Report Third Quarter 2021 Financial Results and Provide Business Update on November 10, 2021 Business Wire - 11/3/2021 8:00:00 AM
OpRegen® Data Update to Be Featured at 2021 American Academy of Ophthalmology Annual Meeting in Presentation by Michael S. Ip, M.D. Business Wire - 10/26/2021 8:00:00 AM
Lineage to Be Featured in B. Riley Securities Fall 2021 “Growth Biotech Best Ideas” Virtual Series on October 18, 2021 Business Wire - 10/18/2021 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/12/2021 4:28:22 PM
Promising New OpRegen® Clinical Data Featured at 54th Annual Retina Society Meeting in Podium Presentation by Christopher D. Riemann, M.D. Business Wire - 9/30/2021 10:52:00 AM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 9/28/2021 4:17:13 PM
Lineage to Present at the 2021 Cantor Virtual Global Healthcare Conference on September 27, 2021 Business Wire - 9/20/2021 8:00:00 AM
Data From Ongoing Clinical Trial Continues to Demonstrate a Single Administration of OpRegen® Can Provide Anatomical and Functional Improvements in Patients With Dry AMD With Geographic Atrophy Business Wire - 9/15/2021 9:00:00 AM
Opregen® Data Update Will Be Featured at 54th Annual Retina Society Meeting in Podium Presentation by Christopher D. Riemann, M.D. Business Wire - 9/13/2021 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/2/2021 4:21:25 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 9/2/2021 4:16:55 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 9/2/2021 6:06:45 AM
Lineage Announces Appointment of General Counsel Business Wire - 9/1/2021 8:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/12/2021 4:22:53 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/12/2021 4:11:45 PM
Lineage Cell Therapeutics EPS beats by $0.01, misses on revenue Seeking Alpha - 8/12/2021 4:07:17 PM
Lineage Reports Second Quarter 2021 Financial Results and Highlights Additional Progress From Clinical Cell Therapy Programs Business Wire - 8/12/2021 4:05:00 PM
ahab333   Tuesday, 01/29/19 01:18:17 PM
Re: HonTer post# 1137
Post # of 1339 
see POST #1135 for whats moving the stock - GLTU

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences